Ibrutinib, a recently approved inhibitor of Bruton's tyrosine kinase (BTK), has shown great efficacy in patients with high-risk CLL. Nevertheless, there are few data regarding its use in patients who relapsed after allogeneic stem cell transplantation (alloSCT). We report clinical data from five CLL patients treated with ibrutinib for relapse after first or even second allogeneic transplantation. Additionally, we performed analyses on cytokine levels and direct measuring of CD4 Th1 and CD4 Th2 cells to evaluate possible clinically relevant immunomodulatory effects of ibrutinib. All patients achieved partial responses including one minimal residual disease (MRD)-negative remission. Within 1 year of follow-up, no relapse was observed. One patient died of severe pneumonia while on ibrutinib treatment. Beside this, no unexpected adverse events were observed. Flow cytometry and analyses of T cellmediated cytokine levels (IL10 and TNFα) did not reveal substantial changes in T-cell distribution in favor of a CD4 Th1 T-cell shift in our patients. No acute exacerbation of GvHD was reported. In conclusion, these results support further evaluation of ibrutinib in CLL patients relapsing after alloSCT.
INTRODUCTION
Allogeneic stem cell transplantation (alloSCT) is regarded as a standard treatment for selected younger CLL patients with high-risk features of the disease (refractoriness to purine-analog treatment, short response to an adequate immune-chemotherapy or high-risk cytogenetic abnormalities including deletion 17p, TP53 mutation or a complex-aberrant karyotype).
1 Despite the curative potential of the method, up to 50% of patients may experience relapse even after alloSCT. 2 Treatment of this group of patients represents a challenge. In 2014 ibrutinib, a first-in-class small molecule and irreversible inhibitor of Bruton's tyrosine kinase (BTK), was approved for the treatment of patients with CLL. [3] [4] [5] Ibrutinib blocks the intracellular signaling cascade of B-cell receptor activation. This leads to the inhibition of proliferation and survival of malignant B cells. Further, changes in chemokine and integrin levels, responsible for migration and homing of lymphocytes, have been demonstrated. [6] [7] [8] Ibrutinib has shown remarkable efficacy in patients with relapsed or refractory CLL after multiple lines of therapy and with a deletion 17p or TP53 mutations. 4, 5 Interestingly, ibrutinib also inhibits other kinases like the interleukin-2 inducible kinase (ITK), 9 which is involved in TCR signaling. The immunosuppressive effect was exclusively found in CD4 Th2 cells, because activation of this T-cell subset is dependent on ITK. 10 Th1 cells are mainly involved in cell-mediated immunity by activating macrophages, natural killer cells and CD8 + T cells, and have been associated with the initiation of acute GvHD. 11 On the other hand, Th2 cells are considered to be responsible for the development of chronic GvHD. [12] [13] [14] In vitro assays using blood from patients with CLL and a pre-clinical mouse model demonstrated a shift from Th2 toward Th1 dominated CD4 immunity upon exposure to ibrutinib. 10 This report prompted us to establish immune-monitoring for patients who received ibrutinib after alloSCT. The idea was to withhold ibrutinib in case of a shift of CD4 immunity toward Th1 as a danger signal, which could indicate imminent activation of GvHD.
Here, we report clinical data and the course of lymphocyte subsets and cytokine levels of five patients with relapsed CLL after alloSCT, who received ibrutinib.
MATERIALS AND METHODS Approach
We retrospectively evaluated data of all patients who presented at our institution between February 2014 and November 2014 with relapsed CLL after first or second alloSCT and were treated with single agent ibrutinib (Imbruvica, Janssen, Johnson & Johnson, Titusville, NJ, USA) due to progressive post-transplant disease. The goal of this study was to assess safety, tolerability (hematological/non-hematological toxicity, influence on GvHD) and efficacy (response assessment) of ibrutinib after alloSCT. Measurement of cytokine levels and Th2/Th1 ratio had been implemented during the first 100 days of ibrutinib treatment as a routine safety measure, to assess possible immunomodulatory effects of ibrutinib in allogeneictransplanted patients.
All patients received ibrutinib due to confirmed progression of CLL after alloSCT. Patients were followed after the start of ibrutinib twice-weekly in the first week, bi-weekly in the first month and then on a monthly basis. Follow-up thereafter was dependent on clinical needs. Blood counts, clinical chemistry and samples for immune-monitoring were taken at every visit (immune-monitoring only up to day +100). Assessment of tolerability and response to therapy by clinical examination was performed respectively. The cutoff date for data assessment and follow-up was 12 November 2015.
Complementary data regarding the patients' history of disease (disease characteristics, prior lines of therapy, manifestations and course of GvHD) before the start of ibrutinib had been retrospectively assessed by reviewing the patients' charts. A comprehensive literature search of this topic has been conducted.
Patient characteristics
In total, five patients with relapsed CLL after alloSCT were evaluated. All patients showed high-risk cytogenetics (del17p, complex-aberrant karyotype) or early relapse/refractoriness to a purine analog in front-line therapy.
All but one patient received at least one line of therapy after allogeneic transplantation before the start of ibrutinib. Therapies after allogeneic transplantation included chemotherapy, monoclonal antibodies, donor lymphocyte infusions, systemic steroids and immunomodulatory agents. Additionally, two patients had received a second allogeneic transplantation after relapse following the first alloSCT.
The median age at start of ibrutinib was 61 years (range: 40-70 years). Ibrutinib was started at a median time of 28 months after the most recent allogeneic transplantation (range: 9-52 months), and was intended to be continued until disease progression or the occurrence of serious side effects. Detailed patient characteristics are shown in Table 1 Immune-monitoring and phenotyping
Monitoring of CD4 Th1 and CD4 Th2 T cells as well as measurement of serum cytokines was performed before dosing and on days +3, +7, +14, +28, +56, +84 and +100 following the start of ibrutinib. Whole-blood PBMCs were isolated using density gradient centrifugation on Biocoll (Biocoll Separation Solution, Biochrom AG, Berlin, Germany). CD4 Th1 and . Furthermore, serum cytokines were determined at each visit up to day +100. TNFα was used as the Th1-associated cytokine, and IL10 was used as the Th2-associated cytokine.
RESULTS

Dosage of ibrutinib
All patients were intended to start with the approved daily dosage of 420 mg OD (three capsules, 140 mg each). In two patients, the dosage had to be reduced initially to 140 mg daily due to possible drug-drug interactions with known inhibitors of the CYP-450 enzyme family (voriconazole and cyclosporine A). In one patient, the dose had to be reduced to 280 mg/day due to ibrutinibrelated diarrhea and gastrointestinal discomfort.
Tolerability
All patients were closely monitored for possible adverse reactions (for example, infections, hematological toxicity, gastrointestinal toxicity, bleeding, cardiac abnormalities, rash or dizziness) by clinical evaluation and assessment of blood samples. The most common hematologic side effect was intermittent mild neutropenia (maximum grade 2, common toxicity criteria), which occurred in two of five patients. During the neutropenic phases, no fever was documented in those patients.
Severe infections requiring hospitalization were seen in two patients. The first patient experienced two episodes of respiratory tract infections, which resolved after the use of i.v. antibiotics. The second patient was admitted to hospital with severe pneumonia and died of septic shock and multi-organ dysfunction. The other patients did not report an increased incidence of minor infectious episodes over the time of ibrutinib treatment. Complex karyotype is defined as ⩾ 3 distinct chromosomal abnormalities in more than one metaphase.
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Furthermore, one patient reported persistent diarrhea and gastrointestinal discomfort. Detailed further diagnostics had been undertaken to exclude other causes frequently occurring in patients post alloSCT. Laboratory results and stool diagnostics did not reveal any signs of an infectious focus. A gastroscopy and a coloscopy were conducted, by which an active intestinal GvHD or CMV-associated colitis as possible differential diagnoses could be excluded. Finally, the symptoms were attributed to ibrutinib and the dose was reduced.
Other commonly described side effects (for example, bleeding, cardiac arrhythmia, rash and arthralgia) did not occur in any of our patients.
Graft-versus-host disease
We regularly evaluated the patients for the presence of chronic GvHD. Only one patient had manifestations of active chronic GvHD at the start of ibrutinib. This patient had grade 2 chronic GvHD of the oral cavity according to NIH criteria, and was therefore still treated with systemic immunosuppression (cyclosporine A and prednisolone). During treatment with ibrutinib, GvHD symptoms almost completely resolved despite the taper of immunosuppressive drugs. The other four patients, who did not show any signs of GvHD at the time when ibrutinib was started, did not develop any exacerbation of GvHD over the whole course of ibrutinib treatment.
Response assessment To determine the response of the disease to ibrutinib, all patients were regularly assessed by clinical examination, blood counts and imaging (ultrasound/computed tomography scans).
Modified IWCLL-NCI-WG criteria by Hallek et al. 15 were used for response assessment. Additionally, regular minimal residual disease (MRD)-assessments were performed using 8-color-flow cytometry. According to standard procedures at our institution, the cutoff for MRD measurements with flow cytometry was one CLL cell out of 10 000 leukocytes. 15 All five patients achieved a partial response. Notably, one patient was off-drug for 10 days because of delayed shipping of ibrutinib after achieving a partial response. Two days after stopping ibrutinib, he developed new lymphadenopathy and constitutional symptoms, which resolved completely after restart of ibrutinib.
The median time to response was 56 days (range: 30-84 days). One patient died of pneumonia and multi-organ dysfunction after being on ibrutinib for 376 days. Four patients were still on treatment (509, 487, 444 and 338 days, respectively) at last followup. Recently, one patient turned MRD negative in the peripheral blood after a successful taper of immunosuppressive drugs while being on ibrutinib. The remaining three patients are still MRD positive (Table 2) .
Lymphocyte counts and T-cell sub-populations Absolute lymphocyte counts in peripheral blood increased in all patients within the first 14 days of treatment. Although baseline levels were between 0.5 × 10 9 /L and 2.1 × 10 9 /L, there was a modest but sustained increase in two patients. Absolute lymphocyte counts in the other three patients increased to 8.7-13.4 × 10 9 /L (Figure 2a) . Assessment of T-cell sub-populations showed a decline in the Th2/Th1 ratio in two out of five patients in the first days following initial ibrutinib treatment. There were no relevant changes in two other patients, whereas one patient displayed an increased Th2/Th1 ratio at day +3 of therapy with ibrutinib, which sustained for the duration of the follow-up until day +100 (Figure 2b ).
Cytokine levels Assessment of serum cytokine levels revealed a decrease in TNFα in three patients, whereas levels remained roughly unchanged or increased in one patient, respectively (Figure 3a) . IL10 levels were undetectable at baseline in two patients. In all other patients, IL10 levels decreased within the first days of ibrutinib treatment (Figure 3b ). Suppression below detection levels was observed and sustained in two patients. The third patient only showed a modest suppression at the beginning of the treatment. This patient discontinued ibrutinib at day +60 of treatment and suffered from clinical relapse shortly after. At the same time, serum levels of IL10 rapidly increased. Of note, this increase in IL10 was also accompanied by an increase in TNFα. After restart of ibrutinib, TNFα and IL10 decreased again.
DISCUSSION
Treatment of patients with relapsed CLL after allogeneic HCT is challenging especially with respect to potential side effects. Yet, there is a chance to achieve long-term survival even in this group of patients. Rozovski et al. 16 analyzed the outcome of 52 patients with CLL who relapsed after alloSCT. The median overall survival from relapse after alloSCT was 35 months; and the median overall survival from the time of re-treatment was 21 months. Thus, treatment of relapse after alloSCT can be successful. A few treatment options for salvage therapy after alloSCT have shown moderate efficacy, including monoclonal anti-CD20 antibodies, donor lymphocyte infusions, lenalidomide and standard chemotherapy. [16] [17] [18] [19] [20] Here, we report on the use of ibrutinib as treatment for relapsed CLL patients following alloSCT. In three out of five of our patients, ibrutinib was started after multiple lines of other treatment regimens following post-alloSCT relapse had failed. Two of these patients even had second alloSCT failure. Despite this, ibrutinib demonstrated sustained activity in this small series of patients. Rapid shrinkage of lymphadenopathy and improvement of blood counts were observed in all patients, resulting in a PR achieved by all patients. No patient relapsed under ibrutinib maintenance therapy. Moreover, one patient achieved MRD negativity following prolonged administration of ibrutinib. Rozovsky et al. 16 reported data on five patients who received ibrutinib after failure from alloSCT. Four of these patients responded to therapy and were alive at a 16-month follow-up. A response rate of 88% was reported from 16 patients treated with ibrutinib for relapsed CLL or small lymphocytic leukemia after alloSCT. 21, 22 Current data thus suggest that ibrutinib has comparable efficacy for the treatment of relapse after alloSCT as after standard chemo-immunotherapy. 23 Very limited data are available on long-term administration of ibrutinib after alloSCT. MRDnegative remissions following single agent ibrutinib in patients with relapse after alloSCT have been observed before by Ryan et al. 24 who reported one similar case. Ibrutinib generally has a favorable risk-benefit ratio. It is well tolerated, with mostly mild to modest toxicity and adverse effects.
Frequently occurring clinically relevant adverse events are upper respiratory tract infections, neutropenia, diarrhea, rash, minor bleeding episodes, atrial fibrillation and fatigue. [3] [4] [5] Still, the administration of ibrutinib in allogeneic-transplanted patients has to be carefully considered in view of safety aspects. Patients after alloSCT are generally at a higher risk of infection due to poor immune reconstitution. 25, 26 Previous reports did not observe an increased incidence of severe infections in immunocompromised patients on ibrutinib compared with chemo-immunotherapy. 4, 5 Nevertheless, the adverse events in patients on ibrutinib following allogeneic transplantation may be different. In our cohort, one patient had a fatal infection. This patient had been heavily pretreated. It remained unclear whether this infection was related to ibrutinib. Although the interference of ibrutinib with B-and T-cell signaling may potentially deteriorate immune responses to infectious agents, the limited number of patients reported here do not allow for a valid estimate of the risk of infection on ibrutinib in patients after alloSCT. Future studies need to address this question. Episodes of acute or chronic GvHD may result from interventions, which modulate the immune system. Moreover, ibrutinib is metabolized to several metabolites primarily by cytochrome P450, CYP3A and to a minor extent by CYP2D6. This may cause severe interactions with other drugs being metabolized by the same pathways. For example, ketoconazole increased ibrutinib dosenormalized Cmax and AUC 29-fold and 24-fold, respectively. 27 Thus, drug interactions are a critical issue after alloSCT in patients who stay on anti-infectives or immunosuppressive drugs, especially as no commercial assays are available to test drug levels.
No patient experienced exacerbation of GvHD in our cohort of patients. Immunosuppressive drugs for the treatment of chronic GvHD could be tapered in one patient after several months of treatment with ibrutinib. Moreover, in longitudinal analyses of patients on ibrutinib we did not detect a Th1 shift in the CD4 subsets and the cytokine profile in contrast to what had been reported from pre-clinical studies. 10 A variety of reasons may account for this discrepancy: (i) our patient number was far too low to detect subtle differences; (ii) the Th1 shift was observed ex vivo in CD4 cells from healthy individuals and CLL patients and was confirmed in a pre-clinical mouse model. In vivo analyses of blood from patients following alloSCT may yield different findings; (iii) in the previous study, serum cytokine levels were regarded as surrogate markers for a Th1 shift. No direct monitoring had been performed by measuring Th1 and Th2 CD4 cells to validate the suppression of Th2 immunity toward a Th1 dominated CD4 profile.
Although a Th1 shift of CD4 immunity after alloSCT has been associated with the onset of acute GvHD, [12] [13] [14] episodes of late acute GvHD that were triggered by ibrutinib have not been reported to date.
In the pathogenesis of chronic GvHD, alteration of B-and T-cell homeostasis is known to have a crucial role. It has been reported that B cells from patients with chronic GvHD show increased responsiveness of B-cell receptor and elevated levels of B-cell activating factor, leading to a downstream metabolic activation and resistance to apoptosis of B cells. 28, 29 Additionally, the activation of specific T-helper subsets is supposed to be involved in the development of chronic GvHD. 12 In this context, BTK and ITK have a critical role in the regulation of downstream activation in lymphoid cells. Based on experiments in knockout mice, it has been hypothesized that the inhibition of BTK and ITK might be effective for treatment of chronic GvHD. Furthermore, prolonged administration of ibrutinib ameliorated cGvHD in two complementary murine models: a model interrogating T cell-driven sclerodermatous cGvHD and an antibody-driven model that induces bronchiolar obliterans. 30 Another murine model showed similar results. 31 Finally, a phase I/II trial (NCT 02195869) evaluating ibrutinib for the treatment of steroid-dependent/refractory chronic GvHD showed good tolerability and promising efficacy in the phase I part. 32 Phase II enrollment is ongoing. The correct timing of Ibrutinib following allogeneic transplantation is of essential importance. Up to now, no studies are available comparing the benefit of ibrutinib in a pre-emptive vs postrelapse setting following transplantation. Our patients received ibrutinib 8-38 months after the most recent transplantation. Ibrutinib was generally well tolerated. Importantly, we did not see worsening or new onset of GvHD in any patient. Owing to the good tolerability, ibrutinib should also be evaluated early after alloSCT.
In conclusion, current evidence derived from pre-clinical animal models, retrospective case studies like ours and early results from clinical trials support further evaluation of ibrutinib for the treatment of relapsed CLL after allogeneic transplantation.
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